The DOI matches its Crossref record.
Evaluation of Anti-TGF-β2 Antibody as a New Postoperative Anti-scarring Agent in Glaucoma Surgery
Abstract
PURPOSE: Postoperative subconjunctival wound healing remains the commonest cause of late bleb failure after glaucoma filtration surgery. This study was undertaken to investigate whether the human monoclonal antibody that neutralizes transforming growth factor-beta2 (CAT-152; lerdelimumab) could be used as a postoperative agent to prevent scarring after glaucoma surgery and compared it with 5-fluorouracil (5-FU), to benchmark its potential clinical benefit. METHODS: In a randomized, controlled, masked-observer study, after modified glaucoma surgery, 48 rabbits were randomly allocated to receive a postoperative course of seven subconjunctival injections of CAT-152 (1 mg/mL), 5-FU (50 mg/mL), or no treatment. Bleb characteristics, the presence of subconjunctival drainage, and local reaction to treatment were assessed. Animals were killed on days 10, 21, and 30. Immunohistochemistry, histologic staining and electron microscopy were performed to demonstrate the mechanism of CAT-152-mediated effects on the extracellular matrix. RESULTS: CAT-152 significantly improved surgical outcome (log rank test, P < 0.001) and reduced subconjunctival collagen deposition (P < 0.01) compared with 5-FU and control. Median bleb survival was increased in the CAT-152 group (23.5 days) compared with the 5-FU (20 days) and control (16 days) treatment groups. CAT-152 treatment improved bleb morphology (P < 0.05) and was well tolerated. 5-FU prolonged the duration of corneal epitheliopathy (P < 0.01). CONCLUSIONS: Postoperative administration of CAT-152 significantly improved surgical outcome, reduced subconjunctival scarring, and minimized the risk of corneal side effects compared with the anti-scarring agent 5-FU. These findings suggest that CAT-152 may offer therapeutic benefit as a postoperative agent to prevent subconjunctival scarring after glaucoma filtration surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing
Pakyari, M., Farrokhi, A., Maharlooei, M. K., & Ghahary, A. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0406 · Cited by 614
TGF-β and fibrosis in different organs — molecular pathway imprints
Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C. K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R. W., & Wolf, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.004 · Cited by 576
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis
Walton, K. L., Johnson, K. E., & Harrison, C. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00461 · Cited by 543
Transforming growth factor‐β in stem cells and tissue homeostasis
Xu, X., Zheng, L., Yuan, Q., Zhen, G., Crane, J. L., Zhou, X., & Cao, X. (2018) · Bone Research · doi:10.1038/s41413-017-0005-4 · Cited by 414
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Complexities of TGF-β Targeted Cancer Therapy
Connolly, E. C., Freimuth, J., & Akhurst, R. J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4564 · Cited by 345
Regulation of endothelial cell plasticity by TGF-β
van Meeteren, L. A., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1222-6 · Cited by 333
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation
Shaunak, S., Thomas, S., Gianasi, E., Godwin, A., Jones, E., Teo, I., Mireskandari, K., Luthert, P., Duncan, R., Patterson, S., et al. (2004) · Nature Biotechnology · doi:10.1038/nbt995 · Cited by 331
Self-citationLiu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Targeting the transforming growth factor-β signaling pathway in human cancer
Nagaraj, N. S., & Datta, P. K. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903382609 · Cited by 262
TGF-β signaling in cancer metastasis
Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx123 · Cited by 231
Memarzadeh, F., Varma, R., Lin, L.-T., Parikh, J. G., Dustin, L., Alcaraz, A., & Eliott, D. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2441 · Cited by 117
Bedinger, D., Lao, L., Khan, S., Lee, S., Takeuchi, T., & Mirza, A. M. (2016) · mAbs · doi:10.1080/19420862.2015.1115166 · Cited by 42
“nologies and Genzyme developed monoclonal antibodies specific to indi-vidual ligands, CAT‐152.(48,49) and CT‐192,(50)”
BackgroundInfluential
Metadata
- Authors
- Mead, A. L., Wong, T. T. L., Cordeiro, M. F., Anderson, I. K., & Khaw, P. T.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2003-08-01
- Volume
- 44
- Issue
- 8
- Pages
- 3394
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2032622848
- Cited by
- 225
- References
- 0
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.